1. Home
  2. CCNE vs GYRE Comparison

CCNE vs GYRE Comparison

Compare CCNE & GYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CNB Financial Corporation

CCNE

CNB Financial Corporation

HOLD

Current Price

$26.88

Market Cap

736.3M

Sector

Finance

ML Signal

HOLD

Logo Gyre Therapeutics Inc.

GYRE

Gyre Therapeutics Inc.

HOLD

Current Price

$7.77

Market Cap

755.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CCNE
GYRE
Founded
1865
2002
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
736.3M
755.7M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
CCNE
GYRE
Price
$26.88
$7.77
Analyst Decision
Hold
Strong Buy
Analyst Count
1
2
Target Price
$29.00
$17.00
AVG Volume (30 Days)
101.9K
52.7K
Earning Date
10-30-2025
11-07-2025
Dividend Yield
2.67%
N/A
EPS Growth
N/A
N/A
EPS
1.91
0.04
Revenue
$227,923,000.00
$107,265,000.00
Revenue This Year
$13.84
$11.59
Revenue Next Year
$27.68
$26.31
P/E Ratio
$14.11
$201.07
Revenue Growth
5.27
2.13
52 Week Low
$19.32
$6.11
52 Week High
$28.30
$14.42

Technical Indicators

Market Signals
Indicator
CCNE
GYRE
Relative Strength Index (RSI) 69.72 53.20
Support Level $25.78 $7.36
Resistance Level $26.20 $7.95
Average True Range (ATR) 0.63 0.34
MACD 0.21 0.00
Stochastic Oscillator 89.88 47.75

Price Performance

Historical Comparison
CCNE
GYRE

About CCNE CNB Financial Corporation

CNB Financial Corp is providing integrated financial solutions, which create value for both consumers and businesses. These solutions encompass deposit accounts, private banking, real estate, commercial, industrial, residential and consumer loans and lines of credit, credit cards, treasury services, online banking, mobile banking, merchant credit card processing, remote deposit and accounts receivable handling. It derives revenue through the operations as a full-service bank engaging in a full range of banking activities and services, including trust and wealth management services, for individual, business, governmental, and institutional customers. The company branch are located in Pennsylvania, Ohio, New York and Virginia.

About GYRE Gyre Therapeutics Inc.

Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.

Share on Social Networks: